Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 6/20 | 0.41 |
| ▸ | ERBB2 | P04626 | 6/20 | 0.41 |
| ▸ | MAPT | P10636 | 5/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 4/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | GBA1 | P04062 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 2/20 | 0.39 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.38 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL765587 | 0.91 | KDR (0.40) | EGFRERBB2MAPTGAAKDM4E | |
| SCHEMBL762327 | 0.90 | SORT1 (0.43) | MAPTKDM4ERAB9ANPC1GBA1 | |
| SCHEMBL761907 | 0.90 | KDM4E (0.38) | MAPTKDM4ERAB9ANPC1GBA1 | |
| SCHEMBL742685 | 0.89 | FGFR1 (0.46) | MAPTRAB9ANPC1GBA1KDR | |
| SCHEMBL742990 | 0.88 | MAPK14 (0.40) | MAPTRAB9ANPC1GBA1KDR | |
| SCHEMBL15221920 | 0.87 | GBA1 (0.51) | EGFRERBB2MAPTRAB9ANPC1 | |
| SCHEMBL744917 | 0.86 | MAPK14 (0.43) | MAPTRAB9ANPC1GBA1KDR | |
| SCHEMBL765527 | 0.85 | RAB9A (0.40) | MAPTKDM4ERAB9ANPC1GBA1 | |
| SCHEMBL743360 | 0.85 | FGFR1 (0.38) | EGFRMAPTRAB9ANPC1GBA1 | |
| SCHEMBL742768 | 0.85 | NTRK2 (0.43) | MAPTRAB9ANPC1GBA1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138336-B2 | Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase | BAYER HEALTHCARE LLC (US) | 2012-03-20 | — | — | US | disclosed |
| US-20100273800-A1 | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING CANCER THROUGH INHIBITION OF AURORA KINASE | BAYER HEALTHCARE LLC | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273800-A1 | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING CANCER THROUGH INHIBITION OF AURORA KINASE | AURKC, AURKA, PLK1 | EGFR 1566/4885ERBB2 838/4885MAPT 1008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.